Physicians may be temporarily eligible for payment terms of up to 150 days (previously 100 days), subject to distributor qualification. Ophthalmologists are urged to verify the timing and specific dating terms that apply to their offices with their authorized distributors of record.
Regeneron aims to implement these new temporary terms by April 1, 2020 and to have these new terms apply retroactively for EYLEA (vial or prefilled syringe) purchased on or after March 1, 2020. These temporary payment terms are subject to change and will be evaluated as the COVID-19 situation evolves.
“The COVID-19 pandemic is having a significant impact on patients and ophthalmologists. In some cases, it is limiting patient access to essential care,” said Anne L. Coleman, MD, PhD, president of the American Academy of Ophthalmology. “We will continue to work with the healthcare community to find ways to help our patients and colleagues get through this difficult time. Regeneron’s prompt response to their needs will be extraordinarily beneficial.”
Please contact your specialty distributor with questions or to apply these new terms.
For more on Regeneron’s scientific efforts to help address COVID-19, go to regeneron.com/covid19
For the Academy’s latest coronavirus updates for ophthalmologists, go to aao.org/coronavirus
About the American Academy of Ophthalmology
The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons. A global community of 32,000 medical doctors, we protect sight and empower lives by setting the standards for ophthalmic education and advocating for our patients and the public. We innovate to advance our profession and to ensure the delivery of the highest-quality eye care. Our EyeSmart® program provides the public with the most trusted information about eye health. For more information, visit aao.org.
Original post https://alertarticles.info